A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
KRAS: The Critical Driver and Therapeutic Target for Pancreatic Cancer
2017
Cold Spring Harbor Perspectives in Medicine
RAS genes (HRAS, KRAS, and NRAS) comprise the most frequently mutated oncogene family in human cancer. With the highest RAS mutation frequencies seen with the top three causes of cancer deaths in the United States (lung, colorectal, and pancreatic cancer), the development of anti-RAS therapies is a major priority for cancer research. Despite more than three decades of intense effort, no effective RAS inhibitors have yet to reach the cancer patient. With bitter lessons learned from past failures
doi:10.1101/cshperspect.a031435
pmid:29229669
pmcid:PMC5995645
fatcat:l642nud56ngczb23ekzcr2fiyi